JP2023512287A5 - - Google Patents

Info

Publication number
JP2023512287A5
JP2023512287A5 JP2022546650A JP2022546650A JP2023512287A5 JP 2023512287 A5 JP2023512287 A5 JP 2023512287A5 JP 2022546650 A JP2022546650 A JP 2022546650A JP 2022546650 A JP2022546650 A JP 2022546650A JP 2023512287 A5 JP2023512287 A5 JP 2023512287A5
Authority
JP
Japan
Prior art keywords
cells
gcl
gclm
hiv
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022546650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512287A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/016041 external-priority patent/WO2021155351A1/en
Publication of JP2023512287A publication Critical patent/JP2023512287A/ja
Publication of JP2023512287A5 publication Critical patent/JP2023512287A5/ja
Pending legal-status Critical Current

Links

JP2022546650A 2020-01-31 2021-02-01 化学防護効果を提供するための組成物及び方法 Pending JP2023512287A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062968906P 2020-01-31 2020-01-31
US62/968,906 2020-01-31
PCT/US2021/016041 WO2021155351A1 (en) 2020-01-31 2021-02-01 Compositions and methods for providing chemoprotective effects

Publications (2)

Publication Number Publication Date
JP2023512287A JP2023512287A (ja) 2023-03-24
JP2023512287A5 true JP2023512287A5 (https=) 2024-02-08

Family

ID=77079986

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022546650A Pending JP2023512287A (ja) 2020-01-31 2021-02-01 化学防護効果を提供するための組成物及び方法

Country Status (4)

Country Link
EP (1) EP4096649A4 (https=)
JP (1) JP2023512287A (https=)
CN (1) CN115605084A (https=)
WO (1) WO2021155351A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020195A1 (en) * 1992-04-01 1993-10-14 Fox Chase Cancer Center Method and recombinant cells for providing increased resistance of hematopoietic progenitor cells to toxicity of chemotherapeutic agents
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
WO2015009884A1 (en) * 2013-07-18 2015-01-22 The Hamner Institutes Cell culture media formulations comprising an activator of nad-dependent protein deacteylase and ueses thereof
IL274632B2 (en) * 2017-11-15 2024-12-01 Weird Science Llc Methods and compositions for non-myeloablative bone marrow reconstitution
CA3106403A1 (en) * 2018-07-15 2020-01-23 Enochian BioPharma, Inc. Methods and compositions using recombinant dendritic cells for cancer therapy

Similar Documents

Publication Publication Date Title
TWI728309B (zh) 一種結合ｂｃｍａ的嵌合抗原受體（ｃａｒ）及其應用
JP7374527B2 (ja) α１－アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞
Clément et al. Stem cell manipulation, gene therapy and the risk of cancer stem cell emergence
AU2014342020A1 (en) Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof
JP2021503015A5 (https=)
US12558435B2 (en) Transient inhibition of p53 in gene therapy
IL274632B2 (en) Methods and compositions for non-myeloablative bone marrow reconstitution
JP2021522837A (ja) 造血幹細胞移植のための組成物及び方法
Verhoeyen et al. Gene therapy in Fanconi anemia: a matter of time, safety and gene transfer tool efficiency
JP2023512287A5 (https=)
JP2020517289A5 (https=)
KR20210142652A (ko) 중간엽 줄기 세포들의 비-바이러스 변형
JP2025528163A (ja) キメラｃｄ８－アルファ補助受容体組成物及び使用方法
EP4398916A1 (en) Compositions and methods for treating or preventing autoimmune diseases
WO2017139199A1 (en) Inducible arginase
US20210113662A1 (en) Compositions and methods for the treatment of ischemia and cardiomyopathy
Quinn et al. 122. Genetic Modification of Target Cells by Direct Delivery of Active Protein
JP2026501725A (ja) Ｃｄ３８細胞表面受容体のエピトープ操作
Dib et al. Restoration of the immune system with base editing and non-genotoxic conditioning in a Rag2 point-mutant mouse model
Ceciliano-Porras et al. USE OF INDUCED PLURIPOTENT STEM CELLS FOR HUMAN IMMUNODEFICIENCY VIRUS TREATMENT
IL322547A (en) Compositions and methods for genome editing
Roselli et al. HEMATOPOIETIC DISORDERS
Gori et al. 124. Cas9-Mediated Genome Editing in Hematopoietic Stem/Progenitor Cells
WO2019050841A1 (en) COMPOSITION OF HEMATOPOIETIC STEM CELLS
Jung et al. Genetically Engineered Mesenchymal Stem Cells for Cell and Gene Therapy